A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). (Q42671883)
Jump to navigation
Jump to search
scientific article published on August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). |
scientific article published on August 2010 |
Statements
1 reference
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). (English)
1 reference
Sara A Hurvitz
1 reference
Heather J Allen
1 reference
Rebecca L Moroose
1 reference
David Chan
1 reference
Christopher Hagenstad
1 reference
Steven H Applebaum
1 reference
Giribala Patel
1 reference
Eddie H Hu
1 reference
Nancy Ryba
1 reference
Lii-Shin Lin
1 reference
Hejing Wang
1 reference
John Glaspy
1 reference
Dennis J Slamon
1 reference
Fairooz Kabbinavar
1 reference
1 August 2010
1 reference
1 reference
Identifiers
1 reference